7 Aug 2017 16:24
7 August 2017
Venture Life Group plc
("Venture Life" or "the Company")
Director/PDMR Shareholding
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that it was notified on 7 August 2017 that Peter Bream, a Non-Executive Director of the Company, has purchased 25,000 ordinary shares of 0.3p each in the Company at an average price of 62.6p per share. Following the transaction Mr Bream has a beneficial interest in 25,000 ordinary shares representing 0.07 per cent. of the Company's issued share capital.
Enquiries:
Venture Life Group PLC | +44 (0) 1344 742870 | |||
Jerry Randall, Chief Executive Officer | ||||
Adrian Crockett, Chief Financial Officer | ||||
Northland Capital Partners Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 3861 6625 | |||
Matthew Johnson / Edward Hutton / Margarita Mitropoulou (Corporate Finance) | ||||
Bob Pountney / John Howes (Corporate Broking) | ||||
Turner Pope Investments (TPI) Ltd (Joint Broker) | +44 (0) 20 3621 4120 | |||
James Pope / Ben Turner | ||||
Walbrook PR | venturelife@walbrookpr.com or + 44 (0) 20 7933 8780 | |||
Paul McManus / Anna Dunphy | +44 (0) 7980 541 893 / +44 (0) 7876 741 001 | |||
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Peter Bream | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Venture Life Group plc | ||||
b) | LEI | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.3p each
GB00BFPM8908
| ||||
b) | Nature of the transactions | Acquisition | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
25,000 62.6p | ||||
e) | Date of the transaction | 7 August 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
Venture Life (VLG)